Fujirebio’s Diagnostic Test for Beta-amyloid Plaques Given FDA OK

The U.S. Food and Drug Administration (FDA) has granted marketing permission to a new test that checks for amyloid plaques in people being checked for Alzheimer’s disease. The Lumipulse G β [beta]-Amyloid Ratio (1-42/1-40) test, which will be sold by Fujirebio Diagnostics, is now approved for adults ages 55 and up who are being evaluated for Alzheimer’s and other causes of cognitive decline. “FDA authorization of the Lumipulse G β-Amyloid Ratio (1-42/1-40) test and the…

You must be logged in to read/download the full post.